The effect of FT500 Plus® on ovarian stimulation in PCOS women

Both oxidative stress and polycystic ovary syndrome have been involved in several aspects of female reproduction. In this retrospective observational study, the outcome of controlled ovarian stimulation and follicular microenvironment of twenty-five women affected by PCOS (Group A) have been explored, evaluating the effects of myo-inositol in association with antioxidant activities (FT500 Plus®). Twenty-five untreated-PCOS women (Group B) with similar characteristics served as control group. Although there was no difference in ovarian volume at time zero, this parameter was significantly smaller at the 5-month follow-up in the Group A (11.1 ± 0.9 versus 13.5 ± 1; P = 0.0001). Group A showed a significant increase in the number of MII oocytes (6.3 ± 2.5 versus 4.5 ± 2; P = 0.03) and glutathione peroxidase activity in follicular fluid (15.4 ± 6.2 versus 11 ± 2.2; P = 0.04). FT500 Plus® may be considered in PCOS patient for improving oocyte quality.